RECIST 1.1 and serum thyroglobulin measurements in the evaluation of responses to sorafenib in patients with radioactive iodine-refractory differentiated thyroid carcinoma.
RECIST 1.1 and serum thyroglobulin measurements in the evaluation of responses to sorafenib in patients with radioactive iodine-refractory differentiated thyroid carcinoma.
复制标题
RECIST 1.1 和血清甲状腺球蛋白测量评估放射性碘难治性分化型甲状腺癌患者对索拉非尼的反应
DOI：
10.3892/ol.2013.1424
复制
发表时间：
2013-08
期刊：
影响因子：
2.9
通讯作者：
Li M
中科院分区：
文献类型：
--
作者：
Ruan M;Shen Y;Chen L;Li M
本研究旨在研究实体瘤疗效评价标准（RECIST）1.1和1.0之间的相关性，并探讨甲状腺球蛋白（Tg）测量在评估放射性碘（RAI）难治性分化型甲状腺癌（DTC）患者对索拉非尼的肿瘤缓解中的效用。总共招募了23例RAI难治性DTC患者。在所有具有可测量疾病的患者中进行了RECIST 1.1和1.0的比较。排除抗Tg抗体阳性患者后，在可测量疾病患者中研究RECIST 1.1与Tg之间的相关性，并分析这些患者与仅不可测量疾病患者之间Tg变化随时间的一致性。根据RECIST 1.1和1.0评估的肿瘤缓解在23份记录中的96%一致。然而，根据RECIST1.1，靶病变数量显着低于使用RECIST1.0时。在接受氟脱氧葡萄糖-正电子发射断层扫描（FDG-PET）/计算机断层扫描（CT）的5例患者中，有1例患者确定为疾病进展（PD）。验证了Tg水平与靶病变直径总和之间的相关性，Tg水平的降低百分比显著大于X线照片中的降低百分比，证明了收缩。此外，Tg水平的百分比变化在患有可测量疾病的患者和仅患有不可测量疾病的受试者之间一致。总之，在RAI难治性DTC患者中，RECIST 1.1与RECIST 1.0在评估索拉非尼治疗反应方面高度一致，具有简化程序和补充使用FDG-PET的优势。与RECIST 1.1一致的Tg测量在评价肿瘤缓解方面具有价值。
The present study was designed to investigate the association between response evaluation criteria in solid tumors (RECIST) 1.1 and 1.0, and to explore the utility of thyroglobulin (Tg) measurements in assessing tumor responses to sorafenib in patients with radioactive iodine (RAI)-refractory differentiated thyroid carcinoma (DTC). In total, 23 patients with RAI-refractory DTC were enrolled. A comparison of RECIST 1.1 and 1.0 was performed in all patients with measurable disease. Following the exclusion of patients who were positive for anti-Tg antibody, the correlation between RECIST 1.1 and Tg was investigated in patients with measurable disease, and the concordance of the change in Tg between these patients and the patients with non-measurable disease only was analyzed over time. Tumor responses, assessed by RECIST 1.1 and 1.0, were concordant in 96% of the 23 records. However, the number of target lesions, according to RECIST 1.1, was significantly lower than when using RECIST 1.0. Progressive disease (PD) was identified in one of the five patients who underwent fluorodeoxyglucose-positron emission tomography (FDG-PET)/computed tomography (CT) scanning. A correlation between the Tg levels and the sum of the diameters of the target lesions was verified, with the percentage decrease in Tg levels significantly greater than that in the radiograph, demonstrating shrinkage. Furthermore, the percentage change in Tg levels was consistent between the patients with measurable disease and the subjects with non-measurable disease only. In conclusion, in patients with RAI-refractory DTC, RECIST 1.1 is highly concordant with RECIST 1.0 in the assessment of responses to sorafenib treatment, with the advantage of simplified procedures and the complementary use of FDG-PET. Tg measurements, in concordance with RECIST 1.1, are valuable in the evaluation of tumor responses.
登录
查看更多内容
影响因子：
5.8
作者：
Durante, C.;Haddy, N.;Schlumberger, M.
通讯作者：
Schlumberger, M.
影响因子：
8.4
作者：
Eisenhauer, E. A.;Therasse, P.;Verweij, J.
通讯作者：
Verweij, J.
影响因子：
3.8
作者：
Brose MS;Nutting CM;Sherman SI;Shong YK;Smit JW;Reike G;Chung J;Kalmus J;Kappeler C;Schlumberger M
通讯作者：
Schlumberger M
甲状腺乳头状癌放射性碘难治性肺转移患者对低剂量索拉非尼的反应
影响因子：
6.6
作者：
Chen, Libo;Shen, Yan;Zhu, Ruisen
通讯作者：
Zhu, Ruisen
影响因子：
2.2
作者：
Clark, PM;Beckett, G
通讯作者：
Beckett, G